There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TFPI


TFPI Molecule Information

Name:Tissue factor pathway inhibitor
Target Synonym:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

TFPI Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
TFI-C52H3 Rhesus macaque Rhesus macaque TFPI Protein, His Tag
TFI-H8226 Human Biotinylated Human TFPI Protein, His Tag, ultra sensitivity (primary amine labeling)
TFI-H5226 Human Human TFPI Protein, His Tag (active enzyme)

TFPI Molecule Synonym Name


TFPI Molecule Background

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI References

TFPI Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BAY-1093884 BAY-109; BAY-1093884 Phase 2 Clinical Morphosys Ag, Bayer Ag Hemophilia A; Hemophilia B Details
Marstacimab PF-6741086; PF-06741086 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Hemophilia A; Hemophilia B; Hemorrhage Details
Concizumab NN-7415; mAb-2021; Anti-TFPI; mAbTFPI2021; NNC-172-2021; NNC-0172-2021; NNC-0172-0000-2021 Phase 3 Clinical Novo Nordisk A/S Hemophilia A; Hemophilia B; Hemorrhage Details

This web search service is supported by Google Inc.